Temodar plus an investigational pill for recurrent brain cancer
Treatments studied
Part of Cancer clinical trials.
This Phase 1 study tests an investigational drug (PCI-24781) together with Temodar in people whose high-grade glioma (grade III/IV) has come back after prior treatment. It aims to find a safe dose and see how well the combination may work for recurrent disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed high-grade glioma (grade III or IV) such as glioblastoma, anaplastic astrocytoma, or similar types
- You already had radiation plus the standard chemotherapy Temodar, and your cancer has progressed at least 3 months after chemoradiation (or progression is shown on biopsy/imaging)
- You are 19 years or older
- You are well enough to participate (ECOG performance status 0 to 2) and have recovered from side effects of prior treatment
- Your blood counts, kidney, and liver test results meet required thresholds
- If you can become pregnant, you must use effective birth control and have a recent negative pregnancy test
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
This Phase 1 trial studies whether adding eflornithine to temozolomide (chemotherapy) is safe and potentially helpful for people with newly diagnosed glioblastoma or certain astrocytomas after radiation. It aims to find a workable treatment approach by closely monitoring side effects and early tumor responses.
This trial tests a combination of two drugs—vebreltinib and temozolomide—for people with a type of brain cancer called glioblastoma. It is for those who have already had surgery to remove as much of the tumor as possible.
This trial tests whether adding cannabinoid medicine to temozolomide helps people whose glioblastoma (GBM) has returned. It compares temozolomide plus cannabinoids versus temozolomide alone, using blinded treatment so neither you nor the team knows which option you get.
This Phase 2 study tests ribociclib with either everolimus or temozolomide, depending on the specific brain tumor type. It may help slow tumor growth in children and young adults whose tumor has specific genetic changes and who have had recent standard radiation therapy.
Hear when a new Recurrent High Grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.